Allergen-specific immunotherapy and COVID-19: What happened?
Main Article Content
adherence, allergen immunotherapy, allergic rhinitis, asthma, COVID-19
Background: The COVID-19 infection played a key role in the discontinuation of patient treatment, such as allergen-specific immunotherapy, in chronic diseases.
Objectives: We conducted a retrospective observational study at Verona University Hospital, Verona, Italy, to assess the level of adherence to sublingual immunotherapy (SLIT) in patients affected by allergic rhinitis and mild asthma.
Materials and Methods: We compared and analysed data related to first prescription and collection of 5-grass-pollen 300-index of reactivity (IR) SLIT and tablet lyophilisate, containing 75,000 standardized quality tablet units (SQ-T) allergen extract of grass-pollen from Phleum pratense L, for the five-year period 2017-2021.In particular we considered the group of naïve patients from 2017 who completed pre-COVID treatment (2017-2019) and the group of naïve patients from 2019 who completed treatment during the COVID period (2019-2021). The significance test used was Student’s t-test, and P ˂ 0.05 was considered as statistically significant.
Results: In the three-year period 2017-2019, 264 naïve patients began treatment in 2017, of these 181 continued in 2018, 135 continued in 2019. Instead, for the period 2017–2019, there were 226 naïve patients in 2019; of these 139 continued in 2020, and 102 in 2021.
Conclusions: COVID-19 did not seem to influence adherence to SLIT, which declined independently even in during the pre-pandemic 3-year period.
2. Aytekin ES, Soyer O, Şekerel BE, Şahiner UM. Subcutaneous allergen immunotherapy in children: Real life compliance and effect of COVID-19 pandemic on compliance. Int Arch Allergy Immunol. 2021;182:631–6. 10.1159/000514587
3. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717–25.e5. 10.1016/j.jaci.2011.12.973
4. Senna G, Caminati M, Lockey RF. Allergen immunotherapy adherence in the real world: How bad is it and how can it be improved? Curr Treat Options Allergy. 2015;2:39–53. 10.1007/s40521-014-0037-6
5. Senna G, Caminati M, Canonica GW. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol. 2013;13:656–62. 10.1097/ACI.0000000000000007
6. Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132:353–60. 10.1016/j.jaci.2013.03.013
7. Penagos M, Eifan AO, Durham SR, Scadding GW. Duration of allergen immunotherapy for long-term efficacy in allergic rhinoconjunctivitis. Curr Treat Options Allergy. 2018;5:275–90. 10.1007/s40521-018-0176-2